ResMed (RMD) Competitors

ResMed logo
$237.15 -5.46 (-2.25%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$237.00 -0.15 (-0.06%)
As of 07:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RMD vs. MEDP, EHC, HIMS, MDT, and SYK

Should you buy ResMed stock or one of its competitors? ResMed's main competitors and comparable companies include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Medtronic (MDT), and Stryker (SYK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ResMed compare to Medpace?

ResMed (NYSE:RMD) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

ResMed has a net margin of 27.79% compared to Medpace's net margin of 18.24%. Medpace's return on equity of 99.76% beat ResMed's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed27.79% 26.42% 19.43%
Medpace 18.24%99.76%24.47%

In the previous week, ResMed had 4 more articles in the media than Medpace. MarketBeat recorded 9 mentions for ResMed and 5 mentions for Medpace. Medpace's average media sentiment score of 0.94 beat ResMed's score of 0.65 indicating that Medpace is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$5.65B5.90$1.52B$10.9821.60
Medpace$2.53B7.01$451.12M$18.0435.14

ResMed has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Medpace has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

55.0% of ResMed shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.6% of ResMed shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ResMed presently has a consensus target price of $253.69, indicating a potential upside of 6.98%. Medpace has a consensus target price of $649.27, indicating a potential upside of 2.41%. Given ResMed's stronger consensus rating and higher probable upside, equities research analysts clearly believe ResMed is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39
Medpace
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.23

Summary

Medpace beats ResMed on 9 of the 16 factors compared between the two stocks.

How does ResMed compare to Encompass Health?

Encompass Health (NYSE:EHC) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Encompass Health pays an annual dividend of $0.84 per share and has a dividend yield of 0.6%. ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. Encompass Health pays out 13.1% of its earnings in the form of a dividend. ResMed pays out 24.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Encompass Health has increased its dividend for 2 consecutive years and ResMed has increased its dividend for 13 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

ResMed has lower revenue, but higher earnings than Encompass Health. Encompass Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Encompass Health$5.94B2.18$566.20M$6.4020.63
ResMed$5.65B5.90$1.52B$10.9821.60

Encompass Health currently has a consensus price target of $154.25, indicating a potential upside of 16.81%. ResMed has a consensus price target of $253.69, indicating a potential upside of 6.98%. Given Encompass Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Encompass Health is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Encompass Health
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39

97.3% of Encompass Health shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 1.8% of Encompass Health shares are held by company insiders. Comparatively, 0.6% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Encompass Health has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, ResMed has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

ResMed has a net margin of 27.79% compared to Encompass Health's net margin of 10.17%. ResMed's return on equity of 26.42% beat Encompass Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Encompass Health10.17% 18.35% 8.38%
ResMed 27.79%26.42%19.43%

In the previous week, Encompass Health had 3 more articles in the media than ResMed. MarketBeat recorded 12 mentions for Encompass Health and 9 mentions for ResMed. Encompass Health's average media sentiment score of 1.00 beat ResMed's score of 0.65 indicating that Encompass Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Encompass Health
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ResMed
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Encompass Health and ResMed tied by winning 10 of the 20 factors compared between the two stocks.

How does ResMed compare to Hims & Hers Health?

ResMed (NYSE:RMD) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$5.65B5.90$1.52B$10.9821.60
Hims & Hers Health$2.35B1.60$128.37M-$0.83N/A

ResMed currently has a consensus target price of $253.69, indicating a potential upside of 6.98%. Hims & Hers Health has a consensus target price of $31.53, indicating a potential upside of 96.84%. Given Hims & Hers Health's higher probable upside, analysts plainly believe Hims & Hers Health is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39
Hims & Hers Health
1 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

ResMed has a net margin of 27.79% compared to Hims & Hers Health's net margin of -6.65%. ResMed's return on equity of 26.42% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed27.79% 26.42% 19.43%
Hims & Hers Health -6.65%-9.62%-1.38%

55.0% of ResMed shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 0.6% of ResMed shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hims & Hers Health had 17 more articles in the media than ResMed. MarketBeat recorded 26 mentions for Hims & Hers Health and 9 mentions for ResMed. ResMed's average media sentiment score of 0.65 beat Hims & Hers Health's score of 0.01 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hims & Hers Health
4 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral

ResMed has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market.

Summary

ResMed beats Hims & Hers Health on 11 of the 16 factors compared between the two stocks.

How does ResMed compare to Medtronic?

ResMed (NYSE:RMD) and Medtronic (NYSE:MDT) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$5.65B5.90$1.52B$10.9821.60
Medtronic$36.36B3.54$4.80B$4.0624.77

55.0% of ResMed shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.6% of ResMed shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ResMed has a net margin of 27.79% compared to Medtronic's net margin of 13.93%. ResMed's return on equity of 26.42% beat Medtronic's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed27.79% 26.42% 19.43%
Medtronic 13.93%14.78%7.97%

In the previous week, Medtronic had 25 more articles in the media than ResMed. MarketBeat recorded 34 mentions for Medtronic and 9 mentions for ResMed. ResMed's average media sentiment score of 0.65 beat Medtronic's score of 0.61 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medtronic
14 Very Positive mention(s)
8 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 2.9%. ResMed pays out 24.0% of its earnings in the form of a dividend. Medtronic pays out 70.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 13 consecutive years and Medtronic has raised its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

ResMed has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

ResMed presently has a consensus price target of $253.69, indicating a potential upside of 6.98%. Medtronic has a consensus price target of $104.17, indicating a potential upside of 3.58%. Given ResMed's higher probable upside, equities research analysts clearly believe ResMed is more favorable than Medtronic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39
Medtronic
1 Sell rating(s)
8 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.63

Summary

ResMed beats Medtronic on 11 of the 19 factors compared between the two stocks.

How does ResMed compare to Stryker?

ResMed (NYSE:RMD) and Stryker (NYSE:SYK) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

ResMed presently has a consensus target price of $253.69, indicating a potential upside of 6.98%. Stryker has a consensus target price of $343.77, indicating a potential upside of 9.77%. Given Stryker's stronger consensus rating and higher possible upside, analysts plainly believe Stryker is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39
Stryker
0 Sell rating(s)
7 Hold rating(s)
21 Buy rating(s)
0 Strong Buy rating(s)
2.75

ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. ResMed pays out 24.0% of its earnings in the form of a dividend. Stryker pays out 37.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years and Stryker has increased its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

ResMed has a net margin of 27.79% compared to Stryker's net margin of 13.78%. ResMed's return on equity of 26.42% beat Stryker's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed27.79% 26.42% 19.43%
Stryker 13.78%23.74%11.64%

In the previous week, Stryker had 9 more articles in the media than ResMed. MarketBeat recorded 18 mentions for Stryker and 9 mentions for ResMed. ResMed's average media sentiment score of 0.65 beat Stryker's score of 0.59 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stryker
6 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Stryker has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$5.65B5.90$1.52B$10.9821.60
Stryker$25.12B4.75$3.25B$9.3933.35

55.0% of ResMed shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.6% of ResMed shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ResMed has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

Stryker beats ResMed on 12 of the 19 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RMD vs. The Competition

MetricResMedHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$34.12B$5.92B$7.57B$21.34B
Dividend Yield1.09%1.69%2.48%3.87%
P/E Ratio21.0439.2133.2126.99
Price / Sales5.905.308.283.62
Price / Cash18.7623.4220.7215.35
Price / Book5.614.154.423.50
Net Income$1.52B$143.14M$3.51B$1.07B
7 Day Performance-1.01%-4.70%-5.53%-4.98%
1 Month Performance-3.42%-6.69%-8.71%-5.05%
1 Year Performance-2.77%-1.05%-1.44%4.97%

ResMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RMD
ResMed
4.25 of 5 stars
$237.15
-2.3%
$253.69
+7.0%
-3.3%$34.12B$5.65B21.0411,370
MEDP
Medpace
2.6708 of 5 stars
$672.93
+3.0%
$649.27
-3.5%
+7.1%$18.37B$2.53B36.416,200
EHC
Encompass Health
4.5783 of 5 stars
$140.79
+2.4%
$154.25
+9.6%
+18.2%$13.84B$5.94B22.0042,000
HIMS
Hims & Hers Health
2.8196 of 5 stars
$22.90
-11.9%
$32.43
+41.6%
-55.3%$6.22B$2.35BN/A2,442
MDT
Medtronic
4.4214 of 5 stars
$102.73
+0.9%
$102.88
+0.1%
+0.5%$134.26B$36.36B18.3595,000

Related Companies and Tools


This page (NYSE:RMD) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners